Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Are currently not hospitalized. (Not applicable to participants in treatment arm 22.)~* Have one or more mild or moderate COVID-19 symptoms: Fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, or shortness of breath with exertion. (Not applicable to participants in treatment arm 22.)~* Must have sample taken for test confirming viral infection no more than 3 days prior to starting the drug infusion~* Are males or females, including pregnant females who agree to contraceptive requirements~* Understand and agree to comply with planned study procedures~* Agree to the collection of nasopharyngeal swabs and venous blood. (Not applicable to participants in treatment arms 20-21.)~* The participant or legally authorized representative give signed informed consent and/or assent~Participants in treatment arms 7-9, 13-14, and 18-21 ONLY~* Are greater than or equal to (≥)18 years of age and must satisfy at least one of the following at the time of screening~  * Are pregnant~ * Are ≥65 years of age~ * Have a body mass index (BMI) ≥35~ * Have chronic kidney disease (CKD)~ * Have type 1 or type 2 diabetes~ * Have immunosuppressive disease~ * Are currently receiving immunosuppressive treatment or~ * Are ≥55 years of age AND have:~    * cardiovascular disease (CVD), OR~   * hypertension, OR~   * chronic obstructive pulmonary disease (COPD) or other chronic respiratory disease~* Are 12-17 years of age (inclusive) AND satisfy at least one of the following at the time of screening~  * Are pregnant~ * Have a body mass index (BMI) ≥85th percentile for their age and gender based on CDC growth charts, https://www.cdc.gov/growthcharts/clinical_charts.htm~ * Have sickle cell disease~ * Have congenital or acquired heart disease~ * Have neurodevelopmental disorders, for example, cerebral palsy~ * Have a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19)~ * Have asthma or reactive airway or other chronic respiratory disease that requires daily medication for control~ * Have type 1 or type 2 diabetes~ * Have chronic kidney disease~ * Have immunosuppressive disease, or~ * Are currently receiving immunosuppressive treatment~Participants in treatment arm 22 ONLY~- Are 0 (≥ 32 weeks gestational age AND ≥ 1.5 kilograms \[kg\]) to 17 years of age (inclusive) AND satisfy at least one of the following risk factors at the time of screening~* Are pregnant~* Have a BMI ≥85th percentile for their age and gender based on CDC growth charts, https://www.cdc.gov/growthcharts/clinical_charts.htm~* Have sickle cell disease~* Have congenital or acquired heart disease~* Have neurodevelopmental disorders, for example, cerebral palsy, autism, or Down syndrome (FAIR Health 2020; Spreat et al. 2020)~* Have a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19)~* Have asthma, cystic fibrosis, reactive airways disease or other chronic respiratory disease that requires daily medication for control~* Have type 1 or type 2 diabetes~* Have chronic kidney disease~* Have immunosuppressive disease, or~* Are currently receiving immunosuppressive treatment, or~* Are less than (\<) one year of age.~* Have one or more COVID-19 symptoms~  * Shortness of breath/difficulty breathing~ * Fever~ * Sore throat~ * Nausea~ * Diarrhea~ * Tiredness~ * Headache~ * New loss of taste~ * Nasal congestion/runny nose~ * Chills~ * Stomachache~ * Vomiting~ * Cough~ * Muscle/body aches and pain~ * New loss of smell~ * Poor appetite or poor feeding (in babies)~Participants in treatment arm 23 ONLY:~Must have first positive result sample of current SARS-CoV-2 viral infection ≤3 days prior to start of treatment administration.~Participant can have COVID previously and still meet criteria for this addendum. Positive result needs to be from a current infection.~Are 0 (≥ 38 weeks gestational age and ≥ 3.3 kg) to \<12 years of age at the time of screening, or are 12 to 17 and weighing \<40 kg; and~* Have mild to moderate COVID-19 disease, including one or more COVID-19 symptoms within the last 7 days~* Shortness of breath/difficulty breathing~* Fever~* Sore throat~* Nausea~* Diarrhea~* Tiredness~* Headache~* New loss of taste~* Nasal congestion/runny nose~* Chills~* Malaise~* Vomiting~* Cough~* Muscle/body aches and pain~* New loss of smell~* Poor appetite or poor feeding (in babies under 1 year old)~Exclusion Criteria:~* Have oxygen saturation (SpO2) less than or equal to (≤)93 percent (%) on room air at sea level or ratio of arterial oxygen partial pressure (PaO2 in millimeters of mercury) to fractional inspired oxygen (FiO2) less than (\<)300, respiratory rate greater than or equal to (≥)30 per minute, heart rate ≥125 per minute due to COVID-19~* Require mechanical ventilation or anticipated impending need for mechanical ventilation due to COVID-19~* Have known allergies to any of the components used in the formulation of the interventions~* Have hemodynamic instability requiring use of pressors within 24 hours of randomization~* Suspected or proven serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking intervention~* Have any co-morbidity requiring surgery within \<7 days, or that is considered life-threatening within 29 days~* Have any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study~* Have a history of a positive SARS-CoV-2 test prior to the one serving as eligibility for this study~* Have received an investigational intervention for SARS-CoV-2 prophylaxis within 30 days before dosing~* Have received treatment with a SARS-CoV-2 specific monoclonal antibody~* Have received convalescent COVID-19 plasma treatment~* Have participated in a previous SARS-CoV-2 vaccine study or have received a SARS-CoV-2 vaccine~* Have participated, within the last 30 days, in a clinical study involving an investigational intervention. If the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed~* Are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study~* Mothers who are breast feeding~Participants in Treatment Arm 22 ONLY~* Have a diagnosis of Multisystem Inflammatory Syndrome in Children (MIS-C) in the opinion of the investigator~* Are currently hospitalized for treatment of COVID-19. Other reasons for hospitalization are acceptable.~Participants in treatment arm 23 ONLY~* SpO2 ≤ 93% on room air at sea level, or while on chronic oxygen therapy and/or respiratory support due to underlying non-COVID-19 related comorbidity, respiratory rate ≥30 per minute, and heart rate ≥125 per minute due to COVID-19 (FDA February 2021)~* Require mechanical ventilation or anticipated impending need for mechanical ventilation due to COVID-19~* Have known allergies to any of the components used in the formulation of the interventions~* Have hemodynamic instability requiring use of pressors within 24 hours of randomization~* Suspected or proven serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking intervention~* Have any co-morbidity requiring surgery within 7 days, or that is considered life-threatening within 29 days~* Have any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study.~* Have received treatment with a SARS-CoV-2 specific monoclonal antibody or remdesivir within 90 days before dosing.~* Have received convalescent COVID-19 plasma treatment within 90 days before dosing~* Have participated, within the last 30 days, in a clinical study involving an investigational intervention. If the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed~* Are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study~* Are currently pregnant or breast feeding

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY3819253 (Type: EXPERIMENTAL): 700 mg, 2800 mg, 7000 mg, LY3819253 administered intravenously (IV)
- LY3819253 + LY3832479 (Type: EXPERIMENTAL): 350 mg, 700 mg, 2800 mg LY3819253 + 700 mg, 1400 mg, 2800 mg LY3832479 administered IV or subcutaneously (SQ)
- LY3819253 + LY3832479 (Pediatric Addendum, Arm 22) (Type: EXPERIMENTAL): LY3819253 dose based upon weight (weight Group: ≥40 kilogram (kg) = 700 mg dose, \>20 kg to \<40 kg = 350 mg dose, \>12 kg to 20 kg = 175 mg dose and 1.5 kg to 12 kg = 15 mg/kg dose) and LY3832479 dose based upon weight (weight Group: ≥40 kg = 1400 mg dose, \>20 kg to \<40 kg = 700 mg dose, \>12 kg to 20 kg = 350 mg dose and 1.5 kg to 12 kg = 30 mg/kg dose) administered IV.
- LY3853113 (Pediatric Addendum, Arm 23) (Type: EXPERIMENTAL): LY3853113 dose based upon weight (Weight Group: ≥3.3 to ≤12 kg = 3 mg/kg dose, \>12 to ≤20 kg = 43.75 mg dose, \>20 to \<40 kg = 87.5 mg dose, ≥40 kg = 175 mg dose) administered IV.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered IV

Based on this trial design, predict the completion outcome and termination type (if applicable).